Velo3D posts $20.5M third-quarter sales as balance sheet strengthens, loss persists
The Nasdaq-listed metal 3D printer maker narrowed its financial risk profile, but its own guidance puts positive operating cash flow two years out, in 2028.
Velo3D, a Nasdaq-listed maker of metal additive manufacturing systems and parts for aerospace and defence customers, reported third-quarter 2026 results on 10 November. Sales came to $20.5 million, which the company described as growth of 50%. New orders totalled $28.9 million. The release summary does not give the comparison period behind the growth figure.
Profitability remains out of reach for now. Gross margin improved to 26.5%, but the GAAP net loss for the quarter was $16.7 million. Management said it expects the business to generate positive operating cash flow in 2028.
The balance sheet looks considerably firmer. Cash rose to $75.7 million, while debt fell to $7.4 million. Management also said that substantial doubt about its ability to keep operating as a going concern no longer exists, a significant change in how the company presents its financial position.
On outlook, Velo3D kept its revenue guidance unchanged. It revised its gross margin guidance and lowered its 2026 capital expenditure guidance, though the summary does not state the new figures. The company also said its Forge 1 production campus is now open.
Why it matters
- Velo3D sells into aerospace and defence, so any direct effect on pharma regulatory or pharmacovigilance work is limited.
- Pharma and biotech teams that buy additively manufactured metal parts or equipment can see a supplier with more cash ($75.7M), less debt ($7.4M) and no going-concern warning.
- The company still expects positive operating cash flow only in 2028, a point supplier-risk reviews may weigh alongside the stronger balance sheet.
Company's press release (SEC filing): Velo3D, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
